Evaluate the Safety and Efficacy of Toripalimab Combined With Bevacizumab Versus Sorafenib Therapy for HCC
Status:
Recruiting
Trial end date:
2024-12-31
Target enrollment:
Participant gender:
Summary
This is a prospective, randomized, open-label, parallel-group, active controlled,
multi-center phase III registration clinical study to observe, compare and evaluate the
efficacy and safety of Toripalimab (hereafter referred to as JS001) combined with Bevacizumab
versus Sorafenib as the first-line therapy for advanced HCC This study will enroll the
patients with locally advanced or metastatic hepatocellular carcinoma who could not be
radically cured and not receive any prior systemic therapy. The study will use PFS and OS as
the co-primary endpoints, with approximately 280 patients planned to be enrolled.